$PHLT
Performant Healthcare Inc Stock $phlt

$phlt Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000155069522000069 Filed on November 09, 2022

Income Statement

Concept	2022 Q4	2022 Q3
Revenue	$29.24M	$27.18M
YoY Change	-7.4%	-4.91%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$22.21M	$21.75M
YoY Change	10.59%	12.65%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$1.169M	$1.100M
YoY Change	-10.42%	37.5%
% of Gross Profit
Operating Expenses	$29.04M	$29.49M
YoY Change	2.04%	3.6%
Operating Profit		-$2.314M
YoY Change		-2112.17%
Interest Expense	-$359.0K	$277.0K
YoY Change	-93.41%	-88.43%
% of Operating Profit
Other Income/Expense, Net	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Pretax Income	-$155.0K	-$1.471M
YoY Change	-94.12%	-13.47%
Income Tax	$80.00K	-$11.00K
% Of Pretax Income
Net Earnings	-$235.0K	-$1.460M
YoY Change	-91.08%	-13.66%
Net Earnings / Revenue	-0.8%	-5.37%
Basic Earnings Per Share		-$0.02
Diluted Earnings Per Share	$0.00	-$0.02
COMMON SHARES
Basic Shares Outstanding	74.28M shares	74.02M shares
Diluted Shares Outstanding		74.02M shares

Balance Sheet

Concept	2022 Q4	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$23.38M	$25.59M
YoY Change	34.8%	-50.14%
Cash & Equivalents	$23.38M	$25.59M
Short-Term Investments
Other Short-Term Assets	$3.746M	$2.476M
YoY Change	-29.05%	-47.79%
Inventory
Prepaid Expenses
Receivables	$15.79M	$15.85M
Other Receivables	$3.123M	$3.211M
Total Short-Term Assets	$57.51M	$56.86M
YoY Change	5.12%	-31.22%
LONG-TERM ASSETS
Property, Plant & Equipment	$10.90M	$10.68M
YoY Change	-30.63%	-34.39%
Goodwill	$47.40M	$47.40M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.000M	$970.0K
YoY Change	3.84%	-1.62%
Total Long-Term Assets	$61.33M	$61.42M
YoY Change	-8.85%	-10.04%
TOTAL ASSETS
Total Short-Term Assets	$57.51M	$56.86M
Total Long-Term Assets	$61.33M	$61.42M
Total Assets	$118.8M	$118.3M
YoY Change	-2.58%	-21.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.262M	$785.0K
YoY Change	12.28%	-5.31%
Accrued Expenses	$1.800M	$1.900M
YoY Change	-50.0%	-34.48%
Deferred Revenue	$400.0K	$500.0K
YoY Change	-33.33%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$983.0K	$859.0K
YoY Change	101.02%	-98.21%
Total Short-Term Liabilities	$14.21M	$13.46M
YoY Change	-18.85%	-78.1%
LONG-TERM LIABILITIES
Long-Term Debt	$18.18M	$18.41M
YoY Change	-4.72%
Other Long-Term Liabilities	$881.0K	$1.148M
YoY Change	-24.57%	-62.42%
Total Long-Term Liabilities	$19.07M	$19.56M
YoY Change	-5.86%	540.16%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.21M	$13.46M
Total Long-Term Liabilities	$19.07M	$19.56M
Total Liabilities	$34.35M	$34.38M
YoY Change	-13.18%	-48.34%
SHAREHOLDERS EQUITY
Retained Earnings	-$57.78M	-$57.55M
YoY Change	12.76%	18.39%
Common Stock	$142.3M	$141.4M
YoY Change	6.43%	6.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$84.49M	$83.90M
YoY Change
Total Liabilities & Shareholders Equity	$118.8M	$118.3M
YoY Change	-2.58%	-21.64%

Cashflow Statement

Concept	2022 Q4	2022 Q3
OPERATING ACTIVITIES
Net Income	-$235.0K	-$1.460M
YoY Change	-91.08%	-13.66%
Depreciation, Depletion And Amortization	$1.169M	$1.100M
YoY Change	-10.42%	37.5%
Cash From Operating Activities	-$695.0K	$3.296M
YoY Change	87.84%	-1951.69%
INVESTING ACTIVITIES
Capital Expenditures	$1.387M	-$609.0K
YoY Change	-292.37%	-44.18%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$4.934M
YoY Change	-100.0%	544.97%
Cash From Investing Activities	-$1.387M	$4.325M
YoY Change	85.92%	-1426.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-125.0K	-125.0K
YoY Change	-99.62%	-100.3%
NET CHANGE
Cash From Operating Activities	-695.0K	3.296M
Cash From Investing Activities	-1.387M	4.325M
Cash From Financing Activities	-125.0K	-125.0K
Net Change In Cash	-2.207M	7.496M
YoY Change	-93.5%	-81.88%
FREE CASH FLOW
Cash From Operating Activities	-$695.0K	$3.296M
Capital Expenditures	$1.387M	-$609.0K
Free Cash Flow	-$2.082M	$3.905M
YoY Change	-693.16%	327.71%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001550695
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-35628
	dei	Entity Registrant Name EntityRegistrantName	PERFORMANT FINANCIAL CORPORATION
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-0484934
	dei	Entity Address Address Line1 EntityAddressAddressLine1	333 North Canyons Parkway
	dei	Entity Address City Or Town EntityAddressCityOrTown	Livermore
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94551
	dei	City Area Code CityAreaCode	(925)
	dei	Local Phone Number LocalPhoneNumber	960-4800
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Shell Company EntityShellCompany	false
	dei	Security12b Title Security12bTitle	Common Stock, par value $.0001 per share
	dei	Trading Symbol TradingSymbol	PFMT
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	74278495	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25591000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17347000	usd
CY2022Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	81000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	2203000	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15850000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	20808000	usd
CY2022Q3	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	9735000	usd
CY2021Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	8113000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2395000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3077000	usd
CY2022Q3	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	3211000	usd
CY2021Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	3159000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	56863000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	54707000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10681000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15708000	usd
CY2022Q3	us-gaap	Goodwill Goodwill	47372000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	47372000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2394000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3235000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	970000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	963000	usd
CY2022Q3	us-gaap	Assets Assets	118280000	usd
CY2021Q4	us-gaap	Assets Assets	121985000	usd
CY2022Q3	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	16000	usd
CY2021Q4	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	11000	usd
CY2022Q3	us-gaap	Notes Payable Current NotesPayableCurrent	859000	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	489000	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6532000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8476000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	785000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1124000	usd
CY2022Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2304000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3732000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	531000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	634000	usd
CY2022Q3	us-gaap	Litigation Reserve Current LitigationReserveCurrent	1148000	usd
CY2021Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	1190000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1303000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1862000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	13462000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	17507000	usd
CY2022Q3	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	341000	usd
CY2021Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	416000	usd
CY2022Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	18409000	usd
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	19084000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1365000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1803000	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1148000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1168000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	34384000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	39562000	usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74212000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74212000	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	69281000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	69281000	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	7000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	7000	usd
CY2022Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	141437000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	133662000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-57548000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-51246000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	83896000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	82423000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	118280000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	121985000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	27178000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	28582000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	79942000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	92814000	usd
CY2022Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	21759000	usd
CY2021Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	19686000	usd
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	63101000	usd
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	67071000	usd
CY2022Q3	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	7733000	usd
CY2021Q3	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	8781000	usd
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	23945000	usd
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	29896000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	29492000	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	28467000	usd
	us-gaap	Operating Expenses OperatingExpenses	87046000	usd
	us-gaap	Operating Expenses OperatingExpenses	96967000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2314000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	115000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7104000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4153000	usd
CY2022Q3	pfmt	Gain Loss On Sale Of Recovery Contracts GainLossOnSaleOfRecoveryContracts	0	usd
CY2021Q3	pfmt	Gain Loss On Sale Of Recovery Contracts GainLossOnSaleOfRecoveryContracts	579000	usd
	pfmt	Gain Loss On Sale Of Recovery Contracts GainLossOnSaleOfRecoveryContracts	382000	usd
	pfmt	Gain Loss On Sale Of Recovery Contracts GainLossOnSaleOfRecoveryContracts	2428000	usd
CY2022Q3	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	1120000	usd
CY2021Q3	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	1120000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	277000	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	2394000	usd
	us-gaap	Interest Expense InterestExpense	648000	usd
	us-gaap	Interest Expense InterestExpense	5866000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1471000	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1700000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6250000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7591000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-11000	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-9000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	52000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	61000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-1460000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1691000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6302000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7652000	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74021000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	62127000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	72480000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57512000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74021000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	62127000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	72480000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57512000	shares
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	84425000	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	42871000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-23000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	931000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	540000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	41000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	42649000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-1460000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1691000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	83896000	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	84387000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	82423000	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41980000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-632000	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2212000	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1963000	usd
	pfmt	Adjustments To Additional Paid In Capital Warrants Associated With Notes Payable AdjustmentsToAdditionalPaidInCapitalWarrantsAssociatedWithNotesPayable	5237000	usd
	pfmt	Stock Issued During Period Shares Earn Out Shares Amount StockIssuedDuringPeriodSharesEarnOutSharesAmount	801000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5563000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	41000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	42649000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6302000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7652000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	83896000	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	84387000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6302000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7652000	usd
	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	-40000	usd
	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	-718000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3355000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3883000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	841000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1413000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2212000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1963000	usd
	pfmt	Interest Expense Debt Issuance Costs And Amortization InterestExpenseDebtIssuanceCostsAndAmortization	71000	usd
	pfmt	Interest Expense Debt Issuance Costs And Amortization InterestExpenseDebtIssuanceCostsAndAmortization	2453000	usd
	pfmt	Gain Loss On Sale Of Recovery Contracts GainLossOnSaleOfRecoveryContracts	382000	usd
	pfmt	Gain Loss On Sale Of Recovery Contracts GainLossOnSaleOfRecoveryContracts	2428000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	1120000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4958000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4270000	usd
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	1622000	usd
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	484000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-682000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1245000	usd
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	52000	usd
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-1305000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	7000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-120000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1944000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-3739000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-339000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	422000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-1515000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-1363000	usd
	pfmt	Increase Decrease In Estimated Liability For Appeals And Disputes IncreaseDecreaseInEstimatedLiabilityForAppealsAndDisputes	-42000	usd
	pfmt	Increase Decrease In Estimated Liability For Appeals And Disputes IncreaseDecreaseInEstimatedLiabilityForAppealsAndDisputes	1240000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-997000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1635000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-19000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-445000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2182000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1286000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2198000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2695000	usd
	pfmt	Proceeds From Sale Of Recovery Contracts ProceedsFromSaleOfRecoveryContracts	382000	usd
	pfmt	Proceeds From Sale Of Recovery Contracts ProceedsFromSaleOfRecoveryContracts	3171000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	4934000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	3118000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	476000	usd
	pfmt	Repayments Of Long Term Notes Payable RepaymentsOfLongTermNotesPayable	375000	usd
	pfmt	Repayments Of Long Term Notes Payable RepaymentsOfLongTermNotesPayable	8438000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	2000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	150000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	633000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	5563000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	41000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	42648000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5186000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	33468000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6122000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	35230000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19550000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18296000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25672000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53526000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25591000	usd
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	51323000	usd
CY2022Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	81000	usd
CY2021Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	2203000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25672000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53526000	usd
	pfmt	Recognition Of Earn Out Shares Issued Non Cash Financing Activity RecognitionOfEarnOutSharesIssuedNonCashFinancingActivity	0	usd
	pfmt	Recognition Of Earn Out Shares Issued Non Cash Financing Activity RecognitionOfEarnOutSharesIssuedNonCashFinancingActivity	801000	usd
	pfmt	Recognitionof Warrant Issued Non Cash Financing Activity RecognitionofWarrantIssuedNonCashFinancingActivity	0	usd
	pfmt	Recognitionof Warrant Issued Non Cash Financing Activity RecognitionofWarrantIssuedNonCashFinancingActivity	5237000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	267000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-683000	usd
	us-gaap	Interest Paid Net InterestPaidNet	449000	usd
	us-gaap	Interest Paid Net InterestPaidNet	3413000	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Revenue Recognition Interest RevenueRecognitionInterest	Revenues, Accounts Receivable, Contract Assets, Contract Liabilities, Estimated Liability for Appeals and Disputes The Company derives its revenues primarily from providing audit, recovery, and analytics services. Revenues are recognized upon completion of these services for its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. <div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines revenue recognition through the following steps:</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identification of the contract with a customer</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identification of the performance obligations in the contract</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Determination of the transaction price</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Allocation of the transaction price to the performance obligations in the contract; and</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Recognition of revenue when, or as, the performance obligations are satisfied.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s contracts generally contain a single performance obligation, delivered over time as a series of services that are substantially the same and have the same pattern of transfer to the client, as the promise to transfer the individual services is not separately identifiable from other promises in the contracts and, therefore, not distinct.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s contracts are composed primarily of variable consideration. Fees earned under the Company’s audit and recovery service contracts consist primarily of contingency fees based on a specified percentage of the amount the Company enables its clients to recover. The contingency fee percentage for a particular recovery depends on the type of recovery or claim facilitated.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally either applies the as-invoiced practical expedient where its right to consideration corresponds directly to its right to invoice its clients, or the variable consideration allocation exception where the variable consideration is attributable to one or more, but not all, of the services promised in a series of distinct services that form part of a single performance obligation. As such, the Company has elected the optional exemptions related to the as-invoiced practical expedient and the variable consideration allocation exception, whereby the disclosure of the amount of transaction price allocated to the remaining performance obligations is not required. </span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates variable consideration only if it can reasonably measure the progress toward complete satisfaction of the performance obligation using an output method based on reliable information and recognizes such revenue over the performance period only if it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Any change made to the measure of progress toward complete satisfaction of the Company’s performance obligation is recorded as a change in estimate. The Company exercises judgment to estimate the amount of constraint on variable consideration based on the facts and circumstances of the relevant contract operations and the availability and reliability of data. The Company reviews the constraint on variable consideration at least quarterly. Although the Company believes the estimates made are reasonable and appropriate, different assumptions and estimates could materially impact the amount of variable consideration recognized.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contracts that contain a refund right, these amounts are considered variable consideration and the Company estimates its refund liability for each claim, as needed, and recognizes revenue net of such estimate.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain contracts, consideration can include periodic performance-based bonuses which can be awarded based on the Company’s performance under the specific contract. These performance-based bonuses are considered variable and may be constrained by the Company until there is not a risk of a significant reversal.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has applied the as-invoiced practical expedient or the variable consideration allocation exception to contracts with performance obligations that have an average remaining duration of less than a year.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For healthcare claims audit contracts, the Company may recognize revenue upon delivering its findings from claims audits, when sufficient reliable information is available to the Company for estimating the variable consideration earned based on an output metric that reasonably measures the Company's satisfaction of its performance obligation.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For eligibility-based or COB contracts, the Company recognizes revenue when insurance companies or other responsible parties have remitted payments to its clients.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For customer care / outsourced services, the Company recognizes revenues based on the volume of processed transactions or the quantity of labor hours provided.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For certain recovery contracts, revenue is recognized when the clients collect on amounts owed to them as a result of the Company’s services. For student loan recovery services, loan rehabilitation revenue was recognized when the rehabilitated loans are funded by clients. Bonuses were recognized upon receipt of official notification of bonus awards from customers.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Amounts collected on trade accounts receivable are included in cash used in operating activities in the consolidated statements of cash flows. The Company determines the allowance for doubtful accounts by specific identification. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The allowance for doubtful accounts was $0 at each of September 30, 2022 and December 31, 2021. </span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets were approximately $9.7 million and $8.1 million as of September 30, 2022 and December 31, 2021, respectively. Contract assets relate to the Company’s rights to consideration for services completed during the respective periods, but not invoiced at the reporting date, and receipt of payment is conditional upon factors other than the passage of time. Contract assets primarily consist of commissions the Company estimates it has earned from claims audit findings submitted to healthcare clients. The increase in contract assets primarily resulted from additional consideration earned for services provided to healthcare clients, offset by invoiced amounts.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets are recorded to accounts receivable when the Company's right to payment becomes unconditional, which is generally when healthcare providers have paid our clients. There was no impairment loss related to contract assets for the nine months ended September 30, 2022.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities were $0.5 million and $0.6 million as of September 30, 2022 and December 31, 2021, respectively. The Company’s contract liabilities relate to certain reimbursable costs due to a healthcare client.</span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers of our clients have the right to appeal claims audit findings and may pursue additional appeals if the initial appeal is found in favor of healthcare clients. For eligibility or COB contracts, insurance companies or other responsible parties may dispute the Company’s findings regarding our clients not being the primary payer of healthcare claims. Total estimated liability for appeals and disputes was $1.1 million as of September 30, 2022 and $1.2 million as of December 31, 2021. This represents the Company’s best estimate of the amount probable of being refunded to the Company’s healthcare clients. </span></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that it does not have any material costs related to obtaining or fulfilling a contract that are recoverable and as such, these contract costs are generally expensed as incurred.</span></div>
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	27178000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	28582000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	79942000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	92814000	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2022Q3	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	9700000	usd
CY2021Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	8100000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	500000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	600000	usd
CY2022Q3	us-gaap	Litigation Reserve Current LitigationReserveCurrent	1100000	usd
CY2021Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	1200000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2400000	usd
CY2022Q3	pfmt	Prepaid Expense And Other Assets Prepaid Software Licenses And Maintenance Agreements PrepaidExpenseAndOtherAssetsPrepaidSoftwareLicensesAndMaintenanceAgreements	1600000	usd
CY2022Q3	us-gaap	Prepaid Insurance PrepaidInsurance	200000	usd
CY2022Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	600000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3100000	usd
CY2021Q4	pfmt	Prepaid Expense And Other Assets Prepaid Software Licenses And Maintenance Agreements PrepaidExpenseAndOtherAssetsPrepaidSoftwareLicensesAndMaintenanceAgreements	1400000	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1100000	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	600000	usd
CY2022Q3	us-gaap	Goodwill Goodwill	47400000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	47400000	usd
CY2022Q3	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	34200000	usd
CY2021Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	34200000	usd
	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	reporting_unit
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	600000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1900000	usd
CY2022Q3	pfmt	Workers Compensation Liability Incurred WorkersCompensationLiabilityIncurred	100000	usd
CY2022Q3	pfmt	Accrued Third Party Fees Current AccruedThirdPartyFeesCurrent	100000	usd
CY2022Q3	pfmt	Accrued Interest Debt Current AccruedInterestDebtCurrent	200000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3600000	usd
CY2021Q4	pfmt	Workers Compensation Liability Incurred WorkersCompensationLiabilityIncurred	100000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	82690000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	89961000	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	72009000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	74253000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10681000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15708000	usd
CY2022Q3	us-gaap	Depreciation Depreciation	1100000	usd
CY2021Q3	us-gaap	Depreciation Depreciation	800000	usd
	us-gaap	Depreciation Depreciation	3400000	usd
	us-gaap	Depreciation Depreciation	3200000	usd
CY2022Q3	pfmt	Number Of Buildings Sold NumberOfBuildingsSold	2	building
CY2022Q3	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	1100000	usd
CY2022Q3	us-gaap	Line Of Credit LineOfCredit	19625000	usd
CY2021Q4	us-gaap	Line Of Credit LineOfCredit	20000000	usd
CY2022Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	357000	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	427000	usd
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	600000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	1600000	usd
CY2022Q3	us-gaap	Long Term Debt LongTermDebt	19268000	usd
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	19573000	usd
CY2022Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	859000	usd
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	489000	usd
CY2022Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	18409000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	19084000	usd
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	125000	usd
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	1000000	usd
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	1500000	usd
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	1500000	usd
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	15500000	usd
CY2022Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	19625000	usd
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	500000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	1800000	usd
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y3M18D
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y6M
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.061
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.064
	us-gaap	Operating Lease Payments OperatingLeasePayments	500000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	2100000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	403000000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1337000000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	697000000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	441000000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2878000000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	210000000	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2668000000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	900000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	500000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2200000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2000000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.01
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.01
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	74021000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	62127000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	72480000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57512000	shares
CY2022Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2021Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74021000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	62127000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	72480000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57512000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6721000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11027000	shares

Files In Submission

Name	View Source	Status
pfmt-20220930_def.xml	Edgar Link	unprocessable
0001550695-22-000069-index-headers.html	Edgar Link	pending
0001550695-22-000069-index.html	Edgar Link	pending
0001550695-22-000069.txt	Edgar Link	pending
0001550695-22-000069-xbrl.zip	Edgar Link	pending
ex093022311cert.htm	Edgar Link	pending
ex093022312cert.htm	Edgar Link	pending
ex093022321cert.htm	Edgar Link	pending
ex093022322cert.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pfmt-20220930.htm	Edgar Link	pending
pfmt-20220930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
pfmt-20220930_cal.xml	Edgar Link	unprocessable
pfmt-20220930_lab.xml	Edgar Link	unprocessable
pfmt-20220930_pre.xml	Edgar Link	unprocessable
pfmt-20220930_htm.xml	Edgar Link	completed
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PHLT
Performant Healthcare Inc Stock $phlt

2022 Q4 Form 10-Q Financial Statement

#000155069522000069 Filed on November 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PHLT Performant Healthcare Inc Stock $phlt

2022 Q4 Form 10-Q Financial Statement

#000155069522000069 Filed on November 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PHLT
Performant Healthcare Inc Stock $phlt